The invention relates to the use oftranscriptome-modifying agents in order to preventmalignant cells from undergoing the necessary geneticchanges in order to combat cell insult and survivechemotherapy or radiotherapy. Said combination oftranscriptome-modifying agents comprises agents thatinhibit the DNA methylation machinery plus a substance thatinhibits histone deacetylation. The invention relates to atreatment kit which involves the administration of aneffective dose of hydralazine and valproic acid or a saltof same in the case of magnesium valproate, which isintended for use with radiotherapy or chemotherapy in thetreatment of patients cancer.
